HIV & AIDS

Final results of the HIV prevention study VOICE published

Researchers who conducted VOICE, a major HIV prevention trial involving more than 5,000 women in Africa, describe the study's primary results in this week's issue of the New England Journal of Medicine (NEJM), outlining in ...

HIV & AIDS

Model explains why HIV prevention dosing differs by sex

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection ...

HIV & AIDS

Soy sauce molecule may unlock drug therapy for HIV patients

For HIV patients being treated with anti-AIDS medications, resistance to drug therapy regimens is commonplace. Often, patients develop resistance to first-line drug therapies, such as Tenofovir, and are forced to adopt more ...

Medical research

Long-lasting device protects against HIV and pregnancy

Women's reproductive health may never be the same, thanks to Northwestern University biomedical engineer Patrick Kiser and his first-of-its-kind intravaginal ring that reliably delivers an antiretroviral drug and a contraceptive ...

HIV & AIDS

Dolutegravir plus abacavir-lamivudine beats combo therapy

(HealthDay)—For patients with HIV-1 infection and HIV-1 RNA of 1,000 copies per mL or more, treatment with dolutegravir plus abacavir-lamivudine (DTG-ABC-3TC) is more effective through 48 weeks than combination therapy ...

page 2 from 5